PROCEEDINGS OF THE AUSTRALASIAN SOCIETY OF CLINICAL AND EXPERIMENTAL PHARMACOLOGISTS
1983; Wiley; Volume: 10; Issue: 6 Linguagem: Inglês
10.1111/j.1440-1681.1983.tb00851.x
ISSN1440-1681
Tópico(s)Neuroendocrine regulation and behavior
Resumo1. Effect of chronic haloperidol treatment on D‐2 receptors labelled by ( 3 H)‐spiperone in homogenates of rat corpus striatum . A. L. Gundlach, D. J. de Vries and P. M. Beart 2. The effects of haloperidol and apomorphine on behavioural responses in rats with modified thyroid status . M. A. Joschko, A. D. Crocker and D. H. Overstreet 3. Dopamine (DA) and dihydroxyphenylacetic acid (DOPAC) distribution within the brain and spinal cord of spontaneously hypertensive (SHR) and Wistar‐Kyoto (WK) rats at various ages . L. G. Howes, P. R. Rowe, R. J. Summers and W. J. Louis 4. Dopamine administration into the nucleus accumbens and the retention of conditioned avoidance learning by rats . P. U. Braes, P. M. Gregory and D. M. Jackson 5. Ketanserin, a serotonin‐2 antagonist, inhibits the vasoconstriction but not the vasodilation produced by serotonin . P. L. McLennan and D. A. Taylor 6. A clinical pharmacological study on ketanserin, a new serotonin antagonist . R. W. Bury, A. T. Kacprowicz, V. Iwanov, P. G. Shaw, R. F. W. Moulds 7. The differentiation of receptor activity of leu 5 ‐ and met 5 ‐enkephalin utilizing in vivo pA 2 analysis . M. J. Quinn and M. R. Fennessy 9. The bioavailability of propantheline bromide . D. K. Moses, B. G. Charles, and P. J. Ravenscroft 10. Elimination of amphotericin B in patients with impaired renal function . M. S. Ching, D. J. Morgan, K. Raymond, R. W. Bury, M. L. Mashford, F. W. Gurr and A. A. Somogyif 11. A renal mechanism for the cloflbric acid‐probenecid interaction . P. J. Meffin and D. M. Zilm 12. pH‐Dependent rearrangement of the biosynthetic ester glucuronide of valproic acid (Epilim) to β‐glucuronidase‐resistant forms . R. G. Dickinson and M. J. Eadie 13. Interaction of purines with GABA‐independent ‘central’ but not ‘peripheral’ benzodiazepine binding sites . L. P. Davies, J. H. Skerritt, S. Chen Chow and G. A. R. Johnston 14. Benzodiazepine stimulation of GABA binding–studies with agonists and antagonists . J. H. Skerritt and G. A. R. Johnston 15. Inhibition of binding of [ 3 H]‐batrachotoxinin A 20‐α‐benzoate to sodium channels by the anticonvulsant drugs diphenylhydantoin and carbamazepine . M. Willow and W. A. Catterall 16. Effects of mianserin on noradrenergic mechanisms . A. Rose, M. W. McCulloch and C. Sarantos‐Laska 17. The effect of olfactory bulbectomy (OB) and antidepressant drugs on circadian rhythm and pineal function in the rat . Doreen H. Leigh and K. D. Cairncross 18. Narcotic potency of the n‐alkanes. Janet De Silva, A. J. Christophers and M. W. Nott 19. Hyperactivity following fetal ethanol exposure is due to a delay in the development of the cholinergic neuro‐transmitter system. N. W. Bond 20. Prevention by aminophylline of the renal effects of both hypertonic saline and amphotericin B; possible linkage of tubuloglomerular feedback and nephrotoxicity. J. F. Gerkens and R. A. Branch (introduced by A. J. Smith) 21. Paracetamol toxicity in hamster hepatocytes: Studies with inhibitors of drug metabolism. A. W. Harman and L. J. Fischer (introduced by K. F. Ilett) 22. The mechanism of action of paracetamol protective agents in the mouse. J. O. Miners, R. Drew, J. Attwood, J. Adams and D. J. Birkett 23. Measurement of formation of reactive metabolites of phenacetin in man. M. Veronese, S. McLean and N. Davies 24. Liver injury due to chronic halothane inhalation. J. L. Plummer, P. de la M. Hall, M. J. Cousins, F. N. Bastin and A. H. Ilsley 25. Changes in rat hepatic microsomal mixed function oxidase activity following exposure to halothane. K. M. Knights, G. K. Gourlay and M. J. Cousins 26. Testicular effects of 2,4,5‐trichlorophenoxy‐acetic acid (2,4,5‐T). R. Drew and J. Rowell 27. Plasma concentrations of unbound phenytoin in the management of epilepsy. C. Kilpatrick, S. Wanwimolruk and L. M. H. Wing 28. Double‐blind comparison of ranitidine and cimetidine in the treatment of chronic gastric ulcer. J. E. Kellow, G. D. Barr, A. E. Cowen, M. Ward, L. Wood and D. W. Piper 29. Comparative evaluation of cimetidine and ranitidine for stress ulcer prophylaxis in the critically ill. D. G. More, R. F. Raper, I. Munro, J. Boutagy and G. M. Shenfield 30. The pharmacokinetics and effect on platelet aggregation of dipyridamole in humans. A. Jenkins, S. Watts, D. Imhoff, B. Duncan, F. Bochner and J. Lloyd 31. A crossover trial of combination α‐ and β‐adrenergic blockade in hypertension. G. S. Stokes, B. A. Mennie and R. Gellatly 32. Different determinants of compliance in epilepsy and hypertension. G. M. Peterson, S. McLean and K. S. Millingen 33. Positive chronotropic responses produced by cardiac α 1 ‐adrenoceptors in the pithed rat. L.‐H. Tung, O. H. Drummer, W. J. Louis and M. J. Rand 34. Effects of partial β‐agonists and phosphodiesterase inhibition on β‐adrenoceptor responsiveness of cultured cardiac cells. A. Bobik, P. Little, J. Campbell and S. Minasian 35. In vitro cardiac activity of isoquinoline derivatives related to papaverine. P. Goadby, R. Foulkes and A. A. Anderson (introduced by C. Raper) 36. Peripheral inhibition of cardiac vagal action by sympathetic adrenergic stimulation. E. K. Potter and D. I. McCloskey (introduced by W. E. Glover) 37. Prostaglandins and the pericardial pressor chemoreflex in dogs. P. N. Nolan, D. E. Luk and J. Staszewska‐Barczak 38. Effect of capsaicin on the Bezold‐Jarisch reflex in the rabbit. Y‐M. Wang, M. L. Mashford and P. J. Harman 39. Correlations between pharmacological responses and structure of human lung parenchyma strips. R. G. Goldie, J. F. Bertram, J. M. Papadimitriou and J. W. Paterson 40. Cholinergic responses in human lung–a structure/function correlation. M. J. B. Finney, N. Berend and J. L. Black 41. Comparisons of in vivo and in vitro responses to histamine in human airways. K. Vincenc, J. Black, A. Woolcock and J. Shaw 42. An interaction betwen leukotriene D4 and histamine on airways resistance in anaesthetized guinea‐pigs. A. G. Stewart, D. C. Thompson and M. R. Fennessy 43. Inhaled prazosin and histamine induced bronchoconstriction. C. R. Jenkins, G. J. Hart, A. B. X. Breslin and G. E. Marlin 44. Prednisolone disposition as a function of dose and oral contraceptive use. B. C. Sallustio, P. J. Meffin, P. M. Brooks and L. M. H. Wing 45. The influence of fatty acids on the binding of prednisolone to albumin. J. M. Potter and D. M. Offerman 46. Midazolam pharmacokinetics in the elderly. M. T. Smith, V. Heazlewood, M. J. Eadie and T. O'R. Brophy 47. Temazepam pharmacokinetics in healthy adults. H. Ghabrial, P. V. Desmond, P. J. Har‐man, M. L. Mashford, B. Westwood, K. J. Breen and A. J. Gijsbers 48. The absorption of aspirin in migraine, and the effect of metoclopramide. L. M. Ross‐Lee, M. J. Eadie, V. Heazlewood and J. H. Tyrer 49. Gastric and intestinal absorption of captopril in the rat. P. J. Worland, O. H. Drummer and B. Jarrott 50. In vivo evidence of presnyaptic a‐adrenoceptors modulating inotropic responses to sympathetic stimulation. R. A. Jarvis, R. Einstein and A. H. Goodman 51. Clonidine fails to inhibit vagal bradycardia: evidence against presynaptic α‐adrenoceptors on cardiac vagal varicosities. M. J. Lew and J. A. Angus 52. Facilitation of sympathetic neuroeffector transmission in guinea‐pig isolated atria by angiotensin I and angiotensin II. J. Ziogas, D. F. Story and M. J. Rand 53. Effect of α‐adrenoreceptor antagonists and neuronal uptake inhibitors on dimethylphenyl‐piperazinium (DMPP)‐induced release of adrenaline from the rabbit adrenal gland. A. R. Collett and D. F. Story 54. Is the carrier system for extraneuronal uptake of catecholamines the same in different cell types? J. J. Cole and S. R. O'Donnell 55. Sites of extraneuronal o‐methylation of isoprenaline in guinea‐pig trachea. L. J. Bryan and S. R. O'Donnell 56. Anti‐inflammatory/anti‐arthritic activity of some copper‐D‐penicillamine complexes. I. R. Garrett and M. W. Whitehouse 57. Determination of response of individual patients with rheumatoid arthritis to auranofin. G. D. Champion, D. Bieri, C. D. Browne, D. Cairns, R. O. Day, G. G. Graham, G. Harris and P. N. Sambrook 58. Studies on the mechanism by which smoking increases the uptake of gold by red blood cells. G. G. Graham, H. M. Jones, T. M. Macpherson and G. D. Champion 59. Anti‐inflammatory drugs in a model of chronic inflammation. R. S. Hirsch and B. Vernon‐Roberts 60. Heavy metal (Au, Pt) nephropathy: studies in normal and inflamed rats. M. W. Whitehouse, I. R. Garrett and B. Vernon‐Roberts 61. Renal function and lithium treatment: a two year prospective study. G. F. S. Johnson, G. E. Hunt and G. G. Duggin 62. Extra‐visceral drug clearance. W. B. Runciman, R. N. Upton, A. H. Ilsley, R. Carapetis, T. M. Shepherd, C. Nancarrow and L. E. Mather 63. β‐Adrenoceptor antagonists as possible inhibitors of drug metabolism in man. L. M. H. Wing, J. O. Miners, B. J. Harrington, K. Lillywhite and K. J. Smith 64. Comparison of β‐adrenoceptor antagonists as modulators of drug metabolism. J. T. Ahokas, C. Davies and P. J. Ravenscroft 65. Guanethidine N‐oxide formation as a measure of flavin‐containing mono‐oxygenase enzyme activity in rat hepatocytes. M. E. McManus, P. H. Grantham, P. J. Wirth, P. P. Roller and S. S. Thorgeirsson 66. Interaction of imidazole drugs with hepatic cytochrome P‐450 dependent enzymes. J. Scott and R. Drew 67. Captopril disulphide conjugates can be reduced back to captopril in vivo. O. H. Drummer and B. Jarrott 68. The rat costo‐uterine muscle: an isolated preparation of potential use for screening drugs acting at β 2 ‐adrenoceptors. J. N. Pennefather and M. L. Hartley 69. Dose‐related effects of ovarian steroid hormones on guinea‐pig myometrial adrenoceptors. M. E. Story, M. L. Hartley and J. N. Pennefather 70. Evidence from binding studies for alpha and beta adrenoceptors associated with rat glomeruli. G. A. McPherson and R. J. Summers 71. A comparison of the effects of phenoxybenzamine and RX781094 in the vas deferens. M. Papanicolaou, M. W. McCulloch and M. J. Rand 72. Ketanserin lowers blood pressure in rats by a‐adrenoceptor blockade. J. F. Marwood and G. S. Stokes 73. Hypotensive response to ketanserin in conscious rabbits: role of α‐adrenoceptors. C. E. Wright, J. A. Angus and G. P. Jackman 74. The influence of platelets on prostanoid release from rat hearts perfused in vitro. M. Purchase and G. J. Dusting 75. The antagonism of the effects of platelet products on a human blood vessel by verapamil, nifedipine and sodium nitrite. R. F. W. Moulds, V. Iwanov and R. L. Medcalf 76. Antagonists of endothelial cell‐mediated relaxation of arterial smooth muscle. T. M. Cocks and J. A. Angus 77. Differences in the mechanism of the endothelium‐dependent relaxing action of acetylcholine in rabbit aorta and dog femoral artery. D. Tang and W. E. Glover 78. Actions of leukotrienes C4, D4 and E, on rat isolated hearts. W. J. Hum, O. L. Woodman and G. J. Dusting 79. Study of the acute toxicity, kinetics and pharmacological action of digitoxigenin glucoside (Dt‐O‐Glu) using the guinea‐pig left atria, mouse, rabbit and open‐chest anaesthetized dog. P. M. Altaian and R. E. Thomas 80. The effect of pH on the inhibitory effect of verapamil, nifedipine and diltiazem on the ATP dependent and DTP independent Ca 2+ binding activity of isolated rat cardiac carcolemmal preparation. J. S. Dillon and W. G. Nayler 81. Theobromine metabolism in man: effects of cimetidine and sulphinpyrazone. D. J. Birkett, J. O. Miners, L. M. H. Wing and J. Attwood 82. Decreased clearance of warfarin after treatment with cimetidine or ranitidine. P. V. Desmond, K. J. Breen, P. J. Harman, M. L. Mashford and B. J. Morphett 83. The influence of chemical structure on the route of metabolism of barbiturates. A. Treston, W. D. Hooper and M. J. Eadie 84. Conjugation of benzoic acid in seven species of marsupial. Almah Awaluddin and S. McLean 85. 25‐Hydroxylation of vitamin D in patients on long‐term anticonvulsant therapy and with parenchymal liver disease. A. Boroky, H. Morris C. Nordin, J. LaBrooy, and F. Bochner 86. Metabolism of tritiated glyceryl trinitrate by human erythrocytes. P. A. Cossum and M. S. Roberts 87. Metronidazole metabolism in the premature neonate. J. Baird‐Lambert, P. E. Doyle, E. Jager‐Roman and N. Buchanan 88. The measurement of motor performance in Parkinson's disease and the evaluation of a sustained release formulation of L‐dopa with benserazide. P. Paull, D. Madden, J. Morris and D. Wade 89. Modulation of dopamine responses by activation of β‐hydroxy phenethylamine receptors. D. F. H. Dougan and D. N. Wade 90. Effect of α‐methyltyrosine on the concentrations of m‐tyramine and α‐methyl m‐tyramine in rat striatum. P. H. Duffield, D. F. H. Dougan, D. N. Wade and A. M. Duffield 91. Radioreceptor assay of the pharmacokinetics of midazolam and chlordiazepoxide. K. M. Taylor, D. M. Paton and R. A. Boas 92. Properties of fentanyl binding to the μ opiate receptor. K. M. Taylor and J. W. Villiger 93. Problems with propranolol as a displacer of [ 3 H)‐dihydroalprenolol for defining β‐receptors in the rat cerebral cortex. E. J. Begg and D. N. Wade 94. The modulation of high affinity ( 3 H)‐spiperone binding by manganese in homogenates of the rat corpus striatum. D. J. de Vries and P. M. Beart 95. The anticonvulsant, carbamazepine, interacts with brain benzodiazepine receptors. J. H. Skerritt and S. Chen Chow 96. Potent theophylline‐like activity of some novel pyrazolopyrimidines. S. Chen Chow, J. H. Skerritt, L. P. Davies, G. A. R. Johnston and D. J. Brown 97. Modification of hypothermic effects of physostigmine by ovariectomy. R. A. Netherton and D. H. Overstreet 98. Design and activity of a new oxygen heterocyclic analogue of GABA. R. D. Allan, G. A. R. Johnston and R. Kazlauskas 99. Selectivity of antidepressants to inhibit amine uptake following in vivo administration. B. Manias and D. A. Taylor 100. Parallel cross‐tolerance to stress and morphine antinociception: no change in endogenous opioid activity following chronic opiate treatment. M. J. Christie, G. B. Chesher, and K. D. Bird 101. Mesenteric vessels from hypertensive rats exhibit an increased responsiveness to serotonin that is inhibited by ketanserin. D. A. Taylor and P. L. McLennan 102. Inhibition of 5‐hydroxytryptophan‐induced wet‐shakes by serotonin‐2 receptor antagonists. C. Y. Yap and D. A. Taylor 103. Neurally‐mediated relaxant effect of serotonin in guinea‐pig distal ileum. E.J. Mylecharane and R. McD. Sutherland 104. Antagonist activity of ketanserin in smooth muscle preparations. R. McD. Sutherland and E. J. Mylecharane 105. Metabolic profile of [ 3 H]‐noradrenaline released by isoprenaline from rabbit atria. C. Sarantos‐Laska, M. W. McCulloch and M. J. Rand 106. Binding of ( 3 H)‐rauwolscine to intact human blood platelets. A. J. Smith and L. M. Stewart 107. Action of opioid‐ and α‐adrenoceptor agonists on neurogenic oedema. R. Lew, G. A. Bentley and I. W. Copeland 108. Sympathetic function in the epididymal and prostatic halves of the rat vas deferens after vasectomy. R. M. DeGaris, M. L. Hartley, J. A. Leedham and J. N. Pennefather 109. Thyroid status and α‐adrenoceptors in rat mesenteric arterioles. G. J. Mammen, E. J. N. Ishac and J. N. Pennefather 110. In vivo and in vitro effects of propylene glycol in human airways. J. Black, K. Yan, C. Salome and J. Shaw 111. Responses of guinea‐pig lung parenchymal strips to drugs affecting adrenoceptors. P. Goad‐by and M. Vadher (introduced by C. Raper) 112. The functional antagonism of carbachol‐induced contractions by β‐adrenoceptor agonists in guinea‐pig isolated tracheal smooth muscle. P. J. Henry, K. M. Lulich and J. W. Paterson 113. Verapamil inhibits thromboxane A2 release from guinea‐pig isolated perfused lungs. S. Ozols and J. P. Seale 114. The effects of fenoterol and selective β‐adrenoceptor antagonists on the release of SRS‐A leukotrienes from human lung fragments. J. M. Hughes, J. P. Seale and D. M. Temple 115. Effect of a new antiallergic compound, SM857, on the release of slow‐reacting substance (leukotrienes) from lung tissue. J. G. Kench, J. P. Seale and D. M. Temple 116. Age‐related changes in responses of human isolated arteries and veins. M. J. Stevens, S. Lipe and R. F. W. Moulds 117. Hyperventilation potentiates the nicotine‐induced depressor chemoreflex in the dog. Denise E. Luk, P. N. Nolan and Janina Staszewska‐Barczak 118. Cardiac sarcolemma during ischaemia and reperfusion: influence of verapamil. M. J. Daly, J. Elz, and W. G. Nayler 119. Structure‐activity relations at peripheral adenosine receptors. D. M. Paton 120. Computer‐assisted anticonvulsant therapy. G. M. Peterson 121. Assessment of efficacy of oral dihydroergotamine in severe orthostatic hypotension from Australian case studies. P. F. Isaac, S. A. Genge, A. Barnes and G. L. Couch 122. The influence of some different antihypertensive drugs on the cardiovascular reaction to isometric exercise. G. Nyberg 123. Comparison of colloidal bismuth subcitrate tablets and liquid in duodenal ulcer healing. J. E. Kellow, G. D. Barr, W. R. J. Middleton and D. W. Piper 124. Effects on β‐blockade on performance in competitive swimming. G. Nyberg and B. Furberg 125. Pharmacokinetic optimization of aminophylline infusion requirements in critically ill asthmatic patients. K. F. Ilett, R. L. Nation, T. E. Oh and B. Silbert 126. Utilization of drug level monitoring in a district hospital. M. Kennedy and W. Beshaw 127. Use of prophylactic antibiotics in children undergoing operations. N. Anderson, D. Cohen, D. Dorman and J. Shaw 128. Drug usage in a coronary care unit. P. Raymond, G. Hale, M. L. Mashford, K. Raymond, J. Roberts, M. Robertson and P. Seo 129. Survey of drug abuse patterns in a casualty department population. J. E. Ray, D. K. Reilly, T. Haavisto, P. D. Paull and R. O. Day 130. Structure‐activity relationships for protein binding of radiocontrast agents. S. Wan‐wimolruk and D. J. Birkett 131. Preliminary pharmacokinetic and pharmacodynamic studies with tizanidine in patients with spasticity. P. Symoniw, V. Heazlewood, P. Maruff and M. J. Eadie 132. Aspirin glucocorticosteroid interaction in man. R. O. Day, G. Harris, M. Brown and G. Graham 133. Analysis and pharmacokinetics of the β‐adrenoceptor agonist ICI 118,587 (Corwin). G. P. Jackman, C. J. Oddie, A. Bobik and G. Jennings 134. Disposition and cardiovascular effects of cimetidine in critically ill patients. R. L. Nation, K. F. Ilett, R. Tjokrosetio, T. E. Oh, P. Cameron and W. Thompson 135. The effect of cimetidine and metoclopramide on the elimination of misonidazole (Ro 07–0582) in man. K. M. Williams, E. J. Begg, D. N. Wade and K. O'Shea 136. Purification of UDP glucuronosyltransferase from mouse liver. P. I. Mackenzie and I. S. Owens (introduced by M. E. McManus) 137. Metabolism of primidone in man. W. D. Hooper, A. Treston, N. W. Jacobsent and M. J. Eadie 138. Influence of cimetidine on procainamide pharmacokinetics in man. A. Somogyi, A. McLean and B. Heinzow 139. Differential effects of hypoxia on the disposition of propranolol and sodium taurocholate by the rat isolated perfused liver. B. Jones, G. Mihaly, R. Smallwood, L. Webster, D. Morgan and M. Madsen 140. Intra‐ and extra‐hepatic carcinomas impair drug metabolism in the rat. P. J. Harman, S. E. Doig, P. V. Desmond, M. L. Mashford, K. J. Breen and B. Gray 141. Kinetic evidence for the involvement of multiple forms of human liver cytochrome P‐450 in the metabolism of acetylaminofluorene. M. E. McManus, R. F. Minchin, P. J. Wirth and S. S. Thorgeirsson 142. Dose‐response curves for the effects of enteric‐coated aspirin on platelet function. P. A. Cossum, J. H. Vial, L. J. McLeodf and M. S. Roberts 143. Converting enzyme inhibition in the rat is accompanied by potentiation of inflammation. A. P. Svolmanis and A. L. A. Boura 144. The effect of route of administration on the distribution and severity of lesions due to a compound whose toxic action is cytochrome P‐450 associated. A. A. Seawright, A. R. Mattocks and J. Hrdlicka 145. Peroxidation of rat liver microsomal membrane lipids induced by methyl mercury. M. Hicks, J. M. Gebicki and K. D. Cairncross 146. Some toxicological and behavioural effects of in utero methyl mercury exposure in the rat. Ann A. Parks, Robyn Can, M. Hicks, J. M. Gebicki and K. D. Cairncross 147. Effects of cimetidine and ranitidine on halothane metabolism and hepatotoxicity. J. L. Plummer, S. Wanwimolruk, M. A. Jenner, P. de la M. Hallt, and M. J. Cousins 148. Cardiovascular and hepatic effects of halothane and isoflurane in a guinea‐pig model of ‘halothane hepatitis'. C. A. Lunam, P. de la M. Hall and M. J. Cousins. (Introduced by M. J. Cousins.) 149. HPLC assays for β‐lactam antibiotics in body fluids. P.J. Harman, Y. M. Wang and M. L. Mashford 150. Comparison of three methods for the routine measurement of phenytoin free fraction during therapeutic drug monitoring. S. Wanwimolruk, D. J. Birkett and L. M. H. Wing 151. Measurement of propantheline bromide in serum by high performance liquid chromatography. B. G. Charles, D. K. Moses and P. J. Ravenscroft 152. The use of 2,5‐diphenyloxazole as a substrate in the assay of AAH. A. Philippides, J. Ahokas. C. Davies, N. Jacobsen and N. Kärki 153. Simultaneous HPLC assay for cimetidine and ranitidine. J. Boutagy, I. A. Munro, D. G. More and G. M. Shenfield 154. The analysis of D‐penicillamine in plasma using fluorescence derivatisation and high performance liquid chromatography. J. O. Miners, I. Fearnley, D. Smith, M. W. Whitehouse, P. Brooks, and D. J. Birkett
Referência(s)